Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-32 (canceled)

Claim 33 (currently amended): A unit dose of a composition, said unit dose consisting essentially of ~~comprising~~ between about 0.0018 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist and a pharmaceutically acceptable carrier for administration to a mammal.

Claim 34 (currently amended): The unit dose of claim 33, consisting essentially of ~~comprising~~ between about 0.09 mg and about 0.45 mg phentolamine mesylate or a molar equivalent of another alpha adrenergic receptor antagonist.

Claim 35 (previously presented): The unit dose of claim 33, wherein said composition is a solution formulated for administration to a mammal by injection, infiltration, or topical application.

Claim 36 (previously presented): The unit dose of claim 35, wherein said solution is formulated for topical application to mucosal tissue.

Claim 37 (previously presented): The unit dose of claim 36, wherein said solution is used to impregnate a wafer, pellet, or cotton ball, for application to mucosal tissue.

Claim 38 (previously presented): The unit dose of claim 33, wherein said composition is a gel or a paste formulated for topical administration to a mammal.

Claim 39 (previously presented): The unit dose of claim 38, wherein said composition is formulated for topical application to mucosal tissue.

Claim 40 (currently amended): The unit dose of claim 33, wherein said another alpha adrenergic receptor antagonist is selected from the group consisting of phentolamine, phentolamine hydrochloride, ~~phentolamine mesylate,~~ tolazoline, yohimbine, rauwolscine, doxazosine, labetalol, prazosine, tetrazosine and trimazosine.

Claim 41 (currently amended): The unit dose of claim 33 ~~40~~, wherein said unit dose consists essentially of ~~alpha adrenergic receptor antagonist is~~ phentolamine mesylate and a pharmaceutically acceptable carrier.

Claim 42 (previously presented): The unit dose of claim 33, wherein said unit dose is present in a container that fits into a standard dental local anesthetic syringe.

Claim 43 (previously presented): The unit dose of claim 42, wherein said container has a volume of between 1.6 ml and 1.8 ml.

Claim 44 (currently amended): The unit dose of claim 33, wherein the unit dose consists essentially of ~~comprises~~ phentolamine mesylate and a pharmaceutically acceptable carrier, said unit dose being present in a container that fits into a standard dental local anesthetic syringe.